Last reviewed · How we verify
Purethal
Purethal, marketed by the Medical University of Silesia, is a drug with a key composition patent expiring in 2028. The primary strength of Purethal lies in its current market presence, leveraging the patent protection to maintain exclusivity. The primary risk is the potential increase in competition post-2028, as generic versions may enter the market upon patent expiry.
At a glance
| Generic name | Purethal |
|---|---|
| Also known as | Vaccine |
| Sponsor | Medical University of Silesia |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM) (PHASE3)
- House Dust Mite Injection Immunotherapy in Elderly Patients. (PHASE3)
- Efficacy and Safety of Birch Pollen Immunotherapy in Local Allergic Rhinitis (PHASE3)
- Grass Pollen Subcutaneous Immunotherapy in Elderly Patients (PHASE4)
- PURETHAL Birch RUSH Study (PHASE4)
- PURETHAL® Mites Dose Range Finding Study in Patients With Persistent Allergic Rhinitis/Rhinoconjunctivitis (PHASE2)
- PURETHAL Grasses Rush Study (PHASE4)
- Study With High Dose PURETHAL Mites in Allergic Rhinitis/Rhinoconjunctivitis Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Purethal CI brief — competitive landscape report
- Purethal updates RSS · CI watch RSS
- Medical University of Silesia portfolio CI